Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Mar 16;2015(3):CD010636.
doi: 10.1002/14651858.CD010636.pub2.

Leukotriene inhibitors for bronchiolitis in infants and young children

Fang Liu  1 , Jing Ouyang, Atul N Sharma, Songqing Liu, Bo Yang, Wei Xiong, Rufu Xu
Affiliations
Meta-Analysis

Leukotriene inhibitors for bronchiolitis in infants and young children

Fang Liu et al. Cochrane Database Syst Rev. .

Abstract

Background: Bronchiolitis is an acute inflammatory illness of the bronchioles common among infants and young children. It is often caused by the respiratory syncytial virus (RSV). Management of bronchiolitis varies between clinicians, reflecting the lack of evidence for a specific treatment approach. The leukotriene pathway has been reported to be involved in the pathogenesis of bronchiolitis. Leukotriene inhibitors such as montelukast have been used in infants and young children with bronchiolitis. However, the results from limited randomised controlled trials (RCTs) are controversial and necessitate a thorough evaluation of their efficacy for bronchiolitis in infants and young children.

Objectives: To assess the efficacy and safety of leukotriene inhibitors for bronchiolitis in infants and young children.

Search methods: We searched CENTRAL (2014, Issue 5), MEDLINE (1946 to April week 4, 2014), EMBASE (1974 to May 2014), CINAHL (1981 to May 2014), LILACS (1982 to May 2014), Web of Science (1985 to May 2014), WHO ICTRP and ClinicalTrials.gov (6 May 2014).

Selection criteria: RCTs comparing leukotriene inhibitors versus placebo or another intervention in infants and young children under two years of age diagnosed with bronchiolitis. Our primary outcomes were length of hospital stay and all-cause mortality. Secondary outcomes included clinical severity score, percentage of symptom-free days, percentage of children requiring ventilation, oxygen saturation, recurrent wheezing, respiratory rate and clinical adverse effects.

Data collection and analysis: We used standard Cochrane Collaboration methodological practices. Two authors independently assessed trial eligibility and extracted data, such as general information, participant characteristics, interventions and outcomes. We assessed risk of bias and graded the quality of the evidence. We used Review Manager software to pool results and chose random-effects models for meta-analysis.

Main results: We included five studies with a total of 1296 participants under two years of age hospitalised with bronchiolitis. Two studies with low risk of bias compared 4 mg montelukast (a leukotriene inhibitor) daily use from admission until discharge with a matching placebo. Both selected length of hospital stay as a primary outcome and clinical severity score as a secondary outcome. However, the effects of leukotriene inhibitors on length of hospital stay and clinical severity score were uncertain due to considerable heterogeneity between the study results and wide confidence intervals around the estimated effects (hospital stay: mean difference (MD) -0.95 days, 95% confidence interval (CI) -3.08 to 1.19, P value = 0.38, low quality evidence; clinical severity score on day two: MD -0.57, 95% CI -2.37 to 1.23, P value = 0.53, low quality evidence; clinical severity score on day three: MD 0.17, 95% CI -1.93 to 2.28, P value = 0.87, low quality evidence). The other three studies compared montelukast for several weeks for preventing post-bronchiolitis symptoms with placebo. We assessed one study as low risk of bias, whereas we assessed the other two studies as having a high risk of attrition bias. Due to the significant clinical heterogeneity in severity of disease, duration of treatment, outcome measurements and timing of assessment, we did not pool the results. Individual analyses of these studies did not show significant differences between the leukotriene inhibitors group and the control group in symptom-free days and incidence of recurrent wheezing. One study of 952 children reported two deaths in the leukotriene inhibitors group: neither was determined to be drug-related. No data were available on the percentage of children requiring ventilation, oxygen saturation and respiratory rate. Finally, three studies reported adverse events including diarrhoea, wheezing shortly after administration and rash. No differences were reported between the study groups.

Authors' conclusions: The current evidence does not allow definitive conclusions to be made about the effects of leukotriene inhibitors on length of hospital stay and clinical severity score in infants and young children with bronchiolitis. The quality of the evidence was low due to inconsistency (unexplained high levels of statistical heterogeneity) and imprecision arising from small sample sizes and wide confidence intervals, which did not rule out a null effect or harm. Data on symptom-free days and incidence of recurrent wheezing were from single studies only. Further large studies are required. We identified one registered ongoing study, which may make a contribution in the updates of this review.

PubMed Disclaimer

Conflict of interest statement

Liu Songqing: none known. Liu Fang: none known. Ouyang Jing: none known. Atul N Sharma: none known. Yang Bo: none known. Xiong Wei: none known. Xu Rufu: none known.

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Montelukast versus placebo, outcome: 1.1 Length of hospital stay.
5
5
Forest plot of comparison: 1 Montelukast versus placebo, outcome: 1.4 Clinical severity score (day 2).
6
6
Forest plot of comparison: 1 Montelukast versus placebo, outcome: 1.5 Clinical severity score (day 3).
1.1
1.1. Analysis
Comparison 1 Montelukast versus placebo, Outcome 1 Length of hospital stay.
1.2
1.2. Analysis
Comparison 1 Montelukast versus placebo, Outcome 2 All‐cause mortality.
1.3
1.3. Analysis
Comparison 1 Montelukast versus placebo, Outcome 3 Clinical severity score (baseline).
1.4
1.4. Analysis
Comparison 1 Montelukast versus placebo, Outcome 4 Clinical severity score (day 2).
1.5
1.5. Analysis
Comparison 1 Montelukast versus placebo, Outcome 5 Clinical severity score (day 3).
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010636

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Amirav 2008 {published and unpublished data}
    1. Amirav I, Kruger N, Borovitch Y, Babai I, Miron D, Zuker M, et al. Double blind placebo controlled randomized trial of montelukast in acute RSV bronchiolitis [Abstract]. European Respiratory Journal 2007;30:499s. - PubMed
    1. Amirav I, Luder AS, Kruger N, Borovitch Y, Babai I, Miron D, et al. A double‐blind, placebo‐controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 2008;122:e1249‐55. - PubMed
    1. Amirav I, Luder AS, Kruger N, Borovitch Y, Babai I, Miron D, et al. A double‐blind, placebo‐controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 2009;123:604. - PubMed
Bisgaard 2008 {published data only}
    1. Bisgaard H, Flores‐Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post‐respiratory syncytial virus bronchiolitis in children. American Journal of Respiratory and Critical Care Medicine 2008;178:854‐60. - PubMed
    1. Bisgaard H, Malice M, Marchal J, Reiss T, Knorr B. Randomized, placebo‐controlled study of montelukast for treatment of post‐RSV‐bronchiolitic respiratory symptoms in children. Allergy 2007;62:127.
    1. Knorr B, Marchal JL, Malice MP, Bisgaard H, Reiss T. Post hoc analysis of the effect of montelukast in treating post RSV bronchiolitic respiratory symptoms in children [Abstract]. European Respiratory Journal 2007;30:461.
    1. Knorr B, Massaad R, Lu S, Newcomb K, Bisgaard H, Reiss T. Safety of montelukast in children with post RSV bronchiolitic respiratory symptoms [Abstract]. European Respiratory Journal 2007;30(Suppl 51):461s.
Kim 2010 {published data only}
    1. Kim C‐K, Choi J, Kim HB, Callaway Z, Shin BM, Kim J‐T, et al. A randomized intervention of montelukast for post‐bronchiolitis: effect on eosinophil degranulation. Journal of Pediatrics 2010;156:749‐54. - PubMed
    1. Kim H, Choi J, Callaway Z, Shin B, Kim J, Fujisawa T, et al. A randomized intervention of montelukast for postbronchiolitis: effect on eosinophil degranulation. Journal of Allergy and Clinical Immunology 2010;125:AB65. - PubMed
Proesmans 2009 {published and unpublished data}
    1. Proesmans M, Sauer K, Govaere E, Raes M, Bilderling G, Boeck K. Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis. Acta Paediatrica 2009;98:1830‐4. - PubMed
Zedan 2010 {published data only}
    1. Zedan M, Gamil N, El‐Assmy M, Fayez E, Nasef N, Fouda A, et al. Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial. Allergy and Asthma Proceedings 2010;31:147‐53. - PubMed

References to studies excluded from this review

Al‐Hamdani 2010 {published data only}
    1. Al‐Hamdani FY. Comparative clinical evaluation of ketotifen and montelukast sodium in asthmatic Iraqi patients. Saudi Pharmaceutical Journal 2010;18:245‐9. - PMC - PubMed
Anonymous 2007 {published data only}
    1. Anonymous. Pre‐school viral wheeze in primary care. Drug & Therapeutics Bulletin 2007;45(3):17‐20. - PubMed
Bacharier 2008 {published data only}
    1. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy & Clinical Immunology 2008;122:1127‐35.e8. - PMC - PubMed
Bai 2010 {published data only}
    1. Bai J, Xu PR. Montelukast in the treatment of bronchiolitis, a multi‐center, randomized, three‐blind, placebo‐controlled trial. Chinese Journal of Evidence‐Based Medicine 2010;10:1011‐5.
Belcaro 2011 {published data only}
    1. Belcaro G, Luzzi R, Cesinaro Di Rocco P, Cesarone MR, Dugall M, Feragalli B, et al. Pycnogenol improvements in asthma management. Panminerva Medica 2011;53:57‐64. - PubMed
Bisgaard 2003 {published data only}
    1. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus post bronchiolitis. American Journal of Respiratory and Critical Care Medicine 2003;167:379‐83. - PubMed
    1. Bisgaard H, Hermansen M, Vrang C, Andersen E, Dybmose G, Braendholt V, et al. Montelukast prevent post‐RSV‐bronchiolitis wheeze. European Respiratory Journal 2002;20:17.
    1. Bisgaard H, Hermansen M, Vrang C, Andersen EA, Dybmose G, Braendholt V, et al. Leukotriene receptor antagonist reduces lung symptoms following respiratory syncytial virus bronchiolitis in infants. American Journal of Respiratory and Critical Care Medicine 2002;165:B38.
    1. Bisgaard H, Study Group on Montelukast, Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus post bronchiolitis. American Journal of Respiratory and Critical Care Medicine 2003;167:379‐83. - PubMed
Bouzaher 2013 {published data only}
    1. Bouzaher A, Phipatanakul W. The effect of montelukast on respiratory symptoms and lung function in wheezy infants. Pediatrics 2013;132(Suppl):47‐8. - PubMed
Bush 2009 {published data only}
    1. Bush A. Practice imperfect ‐ treatment for wheezing in preschoolers. New England Journal of Medicine 2009;360:409‐10. - PubMed
Bush 2010 {published data only}
    1. Bush A. Pre‐school wheezers: not small asthmatic children. Hong Kong Journal of Paediatrics 2010;15:24‐34.
Cook 1992 {published data only}
    1. Cook AJ, Sampson AP, Green CP, Spencer DA, Piper PJ, Price JF. Leukotrienes in infants with acute viral bronchiolitis [abstract]. British Journal of Clinical Pharmacology 1992;34:155.
Cowan 2010 {published data only}
    1. Cowan DC, Hewitt RS, Cowan JO, Palmay R, Williamson A, Lucas SJE, et al. Exercise‐induced wheeze: fraction of exhaled nitric oxide‐directed management. Respirology 2010;15:683‐90. - PubMed
Goswami 2009 {published data only}
    1. Goswami P, Jones SM. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Pediatrics 2009;124(Suppl):147‐8. - PMC - PubMed
Helenius 2004 {published data only}
    1. Helenius I, Lumme A, Ounap J, Obase Y, Rytila P, Sarna S, et al. No effect of montelukast on asthma‐like symptoms in elite ice hockey players. Allergy 2004;59:39‐44. - PubMed
Ji 2007 {published data only}
    1. Ji JZ, Chen ZG, Chen YF, Chen FH, Chen H, Deng L. Effect of leukotriene receptor antagonist on the levels of Th1 and Th2 cytokines in sera of infants with respiratory syncytial virus pneumonia. Chinese Journal of Experimental & Clinical Virology 2007;21:132‐4. - PubMed
Kearns 2008 {published data only}
    1. Kearns GL, Lu S, Maganti L, Li XS, Migoya E, Ahmed T, et al. Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. Journal of Clinical Pharmacology 2008;48:502‐11. - PubMed
Knorr 2006 {published data only}
    1. Knorr B, Maganti L, Ramakrishnan R, Tozzi CA, Migoya E, Kearns G. Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. Journal of Clinical Pharmacology 2006;46:620‐7. - PubMed
Kooi 2008 {published data only}
    1. Kooi EMW, Schokker S, Marike BH, Vries TW, Vaessen‐Verberne AAPH, Molen Thys, et al. Fluticasone or montelukast for preschool children with asthma‐like symptoms: randomized controlled trial. Pulmonary Pharmacology & Therapeutics 2008;21:798‐804. - PubMed
Kozer 2012 {published data only}
    1. Kozer E, Lotem Z, Elgarushe M, Torgovicky R, Cohen R, Cohen HA, et al. RCT of montelukast as prophylaxis for upper respiratory tract infections in children. Pediatrics 2012;129:E285‐90. - PubMed
Nagao 2012 {published data only}
    1. Nagao M, Hiraguchi Y, Hosoki K, Tokuda R, Fujisawa T. Early intervention with pranlukast for infants with recurrent wheeze [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185:A3349.
Nanulescue 2004 {published data only}
    1. Nanulescue MV, Farcau M, Popescu L, Muresan M, Ichim GE. Efficacy of montelukast in recurrent wheezing infants and small children [abstract]. Journal of Allergy and Clinical Immunology 2004;113(Suppl):161.
Neto 2009 {published data only}
    1. Neto HJC, Rosario NA. Recurrent wheezing treatment in infancy: are we treating asthma?. Journal of Allergy and Clinical Immunology 2009;123(Suppl):85.
Ngamphaiboon 2005 {published data only}
    1. Ngamphaiboon J. Montelukast in general pediatric practices. Journal of the Medical Association of Thailand 2005;88(Suppl 4):348‐51. - PubMed
Pelkonen 2013 {published data only}
    1. Pelkonen AS, Malmstrom K, Sarna S, Kajosaari M, Klemola T, Malmberg LP, et al. The effect of montelukast on respiratory symptoms and lung function in wheezy infants. European Respiratory Journal 2013;41:664‐70. - PubMed
Peng 2014 {published data only}
    1. Peng WS, Chen X, Yang XY, Liu EM. Systematic review of montelukast's efficacy for preventing post‐bronchiolitis wheezing. Pediatric Allergy and Immunology 2014;25(2):143‐50. - PubMed
Piedimonte 2005 {published data only}
    1. Piedimonte G, Renzetti G, Auais A, Marco A, Tripodi S, Colistro F, et al. Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatric Pulmonology 2005;40:285‐91. - PubMed
Prapronik 2005 {published data only}
    1. Prapronik M, Bornic Beden A, Cerneic M, Macek V. Leukotriene receptor antagonist (LTRA) montelukast for the treatment of acute bronchiolitis in children under two years of age [abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, CA. 2005:C47 Poster A2.
    1. Praprotnik M, Macek V. Leukotriene receptor antagonist (LTRA) montelukast for the treatment of acute bronchiolitis in infants [abstract]. European Respiratory Journal 2004;24(Suppl 48):504s.
Rivera‐Spoljaric 2009 {published data only}
    1. Rivera‐Spoljaric K, Chinchilli VM, Camera LJ, Zeiger RS, Paul IM, Phillips BR, et al. Signs and symptoms that precede wheezing in children with a pattern of moderate‐to‐severe intermittent wheezing. Journal of Pediatrics 2009;154(6):877‐81.e4. - PMC - PubMed
Santanello 2005 {published data only}
    1. Santanello NC, Norquist JM, Nelsen LM, Williams VSL, Hill CD, Bisgaard H. Validation of a pediatric caregiver diary to measure symptoms of postacute respiratory syncytial virus bronchiolitis. Pediatric Pulmonology 2005;40:31‐8. - PubMed
Straub 2003 {published data only}
    1. Straub DA, Minocchieri S, Moeller A, Hamacher J, Sennhauser FH, Wildhaber JH. Nitric oxide and lung function measurement in wheezy infants following antiinflammatory treatment with montelukast [abstract]. American Thoracic Society 99th International Conference. 2003:A117.
Straub 2005 {published data only}
    1. Straub DA, Moeller A, Minocchieri S, Hamacher J, Sennhauser FH, Hall GL, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. European Respiratory Journal 2005;25:289‐94. - PubMed
Valovirta 2010 {published data only}
    1. Valovirta E, Boza M, Robertson C, Verbruggen N, Smugar S, Knorr B, et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. Allergy: European Journal of Allergy and Clinical Immunology 2010;65:141. - PubMed
Wang 2011 {published data only}
    1. Wang YF, An SY, Zhang JL. Efficacy of montelukast in children with bronchiolitis. Chinese Journal of New Drugs 2011;20:1439‐41.
Widegren 2011 {published data only}
    1. Widegren H, Andersson M, Borgeat P, Flamand L, Johnston S, Greiff L. LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects. Respiratory Medicine 2011;105:997‐1006. - PMC - PubMed
Zentz 2011 {published data only}
    1. Zentz SE. Care of infants and children with bronchiolitis: a systematic review. Journal of Pediatric Nursing 2011;26:519‐29. - PubMed

References to ongoing studies

Wang 2013 {unpublished data only}
    1. Add‐on therapy with montelukast in treatment of bronchiolitis conducted in the First Affiliated Hospital with Nanjing Medical University. Ongoing study October 2013.

Additional references

CDC 2003
    1. Centers for Disease Control and Prevention. Bronchiolitis‐associated outpatient visits and hospitalizations among American Indian and Alaska Native children ‐ United States, 1990‐2000. MMWR. Morbidity and Mortality Weekly Report 2003;52:707‐10. - PubMed
Denny 1977
    1. Denny FW, Collier AM, Henderson FW, Clyde WJ Jr. The epidemiology of bronchiolitis. Pediatric Research 1977;11:234‐6. - PubMed
Farley 2014
    1. Farley R, Spurling GKP, Eriksson L, Mar CB. Antibiotics for bronchiolitis in children under two years of age. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD005189.pub4] - DOI - PMC - PubMed
Fernandes 2013
    1. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD004878.pub4] - DOI - PMC - PubMed
Gadomski 2014
    1. Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD001266.pub4] - DOI - PMC - PubMed
GRADE 2009
    1. GRADE. The GRADE Working Group, GRADE handbook for grading quality of evidence and strength of recommendation version 3.2. Available from http://www.gradeworkinggroup.org 2009.
Halfhide 2008
    1. Halfhide C, Smyth RL. Innate immune response and bronchiolitis and preschool recurrent wheeze. Paediatric Respiratory Reviews 2008;9(4):251‐62. - PMC - PubMed
Hartling 2011
    1. Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, et al. Epinephrine for bronchiolitis. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD003123.pub3] - DOI - PubMed
Hervas 2012
    1. Hervas D, Reina J, Yanez A, Valle JM, Figuerola J, Hervas JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non‐RSV bronchiolitis. European Journal of Clinical Microbiology and Infectious Diseases 2012;31:1975‐81. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester: Wiley‐Blackwell.
Koehoorn 2008
    1. Koehoorn M, Karr CJ, Demers PA, Lencar C, Tamburic L, Brauer M. Descriptive epidemiological features of bronchiolitis in a population‐based cohort. Pediatrics 2008;122:1196‐203. - PubMed
Langley 2003
    1. Langley JM, LeBlanc JC, Smith B, Wang EE. Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980‐2000. Journal of Infectious Diseases 2003;188:1764‐7. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Mansbach 2005
    1. Mansbach JM, Emond JA, Camargo CA Jr. Bronchiolitis in US emergency departments 1992 to 2000: epidemiology and practice variation. Pediatric Emergency Care 2005;21:242‐7. - PubMed
Mohapatra 2008
    1. Mohapatra SS, Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clinical Microbiology Reviews 2008;21:495‐504. - PMC - PubMed
Quintero 2007
    1. Quintero DR, Gershan WM. Diagnosis and treatment of infants with bronchiolitis. Journal of Clinical Outcomes Management 2007;14:205‐10.
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Scow 2007
    1. Scow DT, Luttermoser GK, Dickerson KS. Leukotriene inhibitors in the treatment of allergy and asthma. American Family Physician 2007;75:65‐70. - PubMed
Shay 1999
    1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis‐associated hospitalizations among US children, 1980‐1996. JAMA 1999;282:1440‐6. - PubMed
Tania 2006
    1. Tania B, Huedo M, Julio SM, Fulgencio MM, Juan B. Assessing heterogeneity in meta‐analysis: Q statistic or I squared index?. CHIP Documents 2006:paper 19.
Wang 1992
    1. Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. American Review of Respiratory Disease 1992;145:106‐9. - PubMed
Worrall 2008
    1. Worrall G. Bronchiolitis. Canadian Family Physician 2008;54(5):742‐3. - PMC - PubMed
Zhang 2013
    1. Zhang L, Mendoza‐Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD006458.pub3] - DOI - PubMed

References to other published versions of this review

Liu 2013
    1. Liu F, Ouyang J, Sharma AN, Liu S, Yang B, Xiong W, et al. Leukotriene inhibitors for bronchiolitis in infants and young children. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010636] - DOI - PMC - PubMed

LinkOut - more resources